Day One Announces Pricing of Upsized Initial Public Offering

Rhea-AI Summary

Day One Biopharmaceuticals (Nasdaq: DAWN) has priced its initial public offering (IPO) at $16.00 per share, offering 10,000,000 shares. The expected gross proceeds are $160 million, before deductions. Trading begins on Nasdaq on May 27, 2021, with closing anticipated by June 1, 2021, pending customary conditions. Underwriters, including J.P. Morgan and Cowen, have a 30-day option for an additional 1,500,000 shares. The company focuses on targeted therapies for genetically defined cancers, particularly in pediatric patients.

Positive

• Initial public offering priced at $16.00 per share, raising $160 million.
• Funds will support development of targeted cancer therapies.
• Company's focus on unmet needs in pediatric cancer treatment.

Negative

• Potential dilution risk if underwriters exercise the option for additional shares.

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Day One. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Day One, are expected to be $160.0 million. The shares are expected to begin trading on the Nasdaq Global Select Market on May 27, 2021 under the ticker symbol “DAWN.” The offering is expected to close on June 1, 2021, subject to the satisfaction of customary closing conditions. In addition, Day One has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

J.P. Morgan, Cowen and Piper Sandler are acting as joint bookrunning managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on May 26, 2021. The offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Day One Biopharmaceuticals, Inc.

Day One is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Day One’s name was inspired by the “The Day One Talk”¹ that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with relapsed or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, highly-selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK). Day One is based in South San Francisco.

^{¹ Jennifer W. Mack and Holcombe E. Grier; Journal of Clinical Oncology 2004 22:3, 563-566}

Contact:
1AB
Dan Budwick
dan@1abmedia.com

FAQ

What is Day One Biopharmaceuticals' stock symbol?

The stock symbol for Day One Biopharmaceuticals is DAWN.

When did Day One Biopharmaceuticals' IPO stock begin trading?

Day One Biopharmaceuticals' IPO stock is expected to begin trading on May 27, 2021.

How much money is Day One Biopharmaceuticals aiming to raise from its IPO?

Day One Biopharmaceuticals aims to raise $160 million from its IPO.

What is the purpose of Day One Biopharmaceuticals' IPO?

The IPO funds will be used to develop targeted therapies for genetically defined cancers.

What is the expected closing date for Day One Biopharmaceuticals' IPO?

The expected closing date for Day One Biopharmaceuticals' IPO is June 1, 2021.